Clinical Updates & Insights

Share
Print

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up

Manage Preferences

211 Clinical Updates found

Clinical Update

Alterations in Driver Genes Predict Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma

In patients with resected pancreatic ductal adenocarcinoma, alterations in KRAS and TP53 were associated with worse outcomes, whereas alterations in homologous recombination deficiency genes were associated with favorable prognoses.

  • Thursday, July 16, 2020

Clinical Update

Severity of COVID-19 in Patients with Lung Cancer: Not Driven by Cancer or Cancer Treatments

Our study, published recently in the Annals of Oncology, suggests that the greatest determinants of COVID-19 severity were patient features and comorbidities, such as a history of heavy smoking and chronic obstructive pulmonary disease (COPD).

  • Thursday, July 16, 2020

Clinical Update

CAR T Update Part 1: Learning and Opportunities in Hematologic Cancers

In our paper, published recently in the journal Expert Review of Hematology, we review the main challenges with current CD19-targeted CAR, obstacles to adopting CAR T cell therapy in solid tumors, and various strategies scientists are pursuing to overcome these issues.

  • Thursday, June 11, 2020

Clinical Update

CAR T Update Part 2: Challenges and Opportunities in Solid Tumors

This CAR T Update Part 2 summarizes the unique challenges with using CARS to defeat solid tumors, and how learning from preclinical and clinical research in hematologic malignancies is informing new strategies and research efforts.

  • Thursday, June 11, 2020

Clinical Update

Combination Immunotherapy Meets Primary Endpoint in Phase II Clinical Trial in Advanced Sarcoma

The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.

  • Thursday, June 11, 2020

Clinical Update

Best Practices for Managing Cancer Surgery during the COVID-19 Pandemic

Memorial Sloan Kettering has convened a COVID-19 Operating Room Executive Committee to scrutinize all surgical cases and determine whether they were truly essential and to review needs, resources, and ICU availability.

  • Monday, May 11, 2020

Clinical Update

CAR T Cell Therapy Should Proceed During the COVID-19 Pandemic

Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite Covid-19 according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S. academic institutions.

  • Monday, May 11, 2020

Clinical Update

Evidence-Based Approaches to Defer or Shorten Breast Radiotherapy during the COVID-19 Pandemic

During the early days of the COVID-19 outbreak, a team of radiation oncologists specializing in breast cancer management at Memorial Sloan Kettering Cancer Center reviewed the literature and established recommendations for the safe use of hypofractionated and abbreviated radiation regimens for our patients with breast cancer.

  • Monday, May 11, 2020

Clinical Update

Managing Locally Advanced Rectal Cancer with Short-Course Radiation Therapy During the COVID-19 Pandemic

The pandemic has raised important issues for clinicians, and, after weighing the risks and benefits, the Colorectal Disease Management Team at MSK decided that all patients with locally advanced colorectal cancer will be treated with short-course radiation therapy rather than standard long-course chemoradiation therapy.

  • Monday, May 11, 2020

Clinical Update

The Best Preoperative Assessment Tools for Patients Undergoing Surgery for Secondary Upper Extremity Lymphedema

For the past five years, we have prospectively evaluated patients with secondary lymphedema of the upper extremity who presented for surgical consultation at Memorial Sloan Kettering Cancer Center (MSK).

  • Wednesday, April 8, 2020